on behalf of the Lumiere Study Investigators abstract PURPOSE The aim of this open-label, first-in-setting, randomized phase III trial was to evaluate the efficacy of alisertib, an investigational Aurora A kinase inhibitor, in patients with relapsed/refractory peripheral T-cell lymphoma (PTCL).
INTRODUCTION
Peripheral T-cell lymphoma (PTCL) is a rare, heterogeneous group of non-Hodgkin lymphomas that comprises more than 29 distinct histologic subtypes. 1 The most common subtype, PTCL not otherwise specified (PTCL-NOS), represents approximately 25% of cases (varying across ethnic groups). 2, 3 Although there is no standard of care, most patients receive frontline anthracycline-based chemotherapy, such as cyclophosphamide, doxorubicin, vincristine, prednisone; cyclophosphamide, doxorubicin, vincristine, prednisone plus etoposide; or infusional cyclophosphamide, doxorubicin, vincristine, prednisone plus etoposide. Patients who develop relapsed/refractory PTCL typically experience a dismal outcome, with median progression-free survival (PFS) and overall survival (OS) after first postsystemic therapy relapse or progression of 3.1 and 5.5 months, respectively. 4 At the time of protocol finalization (2011), pralatrexate (antifolate) and romidepsin (histone deacetylase inhibitor) were approved in relapsed/refractory PTCL by the US Food and Drug Administration; however, there was no globally approved therapy in this setting. 5, 6 Brentuximab vedotin, a CD30-directed antibody-drug conjugate, had also been approved by the US Food and Drug Administration but only for systemic anaplastic large-cell lymphoma after failure of one or more prior multiagent chemotherapy regimen. 7 On the basis of the literature showing singleagent activity with small numbers of patients, PTCL expert input, and drug use information outside the United States, gemcitabine (antimetabolite) was selected as a third option for the comparator arm of the trial in addition to pralatrexate and romidepsin. 8, 9 Previously reported overall response rates (ORRs) in relapsed/refractory PTCL were 29% with pralatrexate 6 and 26% with romidepsin. 10 Duration of response (DOR) was more than 1 year with each agent. Both exhibited relatively short PFS but produced durable remissions with acceptable safety profiles; however, given the low response rates, well-tolerated and active agents are still needed in this setting.
Aurora A kinase (AAK) is essential for mitosis, 11 and studies have demonstrated overexpression and upregulation of aurora kinases in PTCL, [12] [13] [14] which supports AAK inhibition as a novel therapeutic strategy. 11, 15 Alisertib (MLN8237) is an investigational, selective, small-molecule AAK inhibitor that demonstrated activity in human tumor cell lines, [16] [17] [18] preclinical models of T-cell and B-cell lymphoma, 19 and in vivo lymphoma models. 20 Phase I studies established the recommended single-agent phase II dose as 50 mg two times per day for 7 days in 21-day cycles. 21, 22 Subsequent phase II studies reported efficacy and tolerability of alisertib across a range of malignancies, 14, [23] [24] [25] including relapsed/ refractory B-cell and T-cell lymphoma, with ORRs of 27% (50% for a cohort of eight patients with noncutaneous T-cell lymphoma) 23 and 30%, 14 respectively.
Lumiere is the first randomized phase III trial in patients with relapsed/refractory PTCL. It aimed to differentiate alisertib from other approved or commonly used drugs and to hasten potential broader approval for patients with relapsed/refractory PTCL.
PATIENTS AND METHODS

Study Design and Patients
This randomized, two-arm, open-label, phase III trial enrolled patients at 105 centers in 27 countries (Data Supplement). The protocol was approved by institutional review boards and/or ethics committees at all sites and was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization Guideline for Good Clinical Practice, including written informed consent and data monitoring.
This study had two primary objectives: to determine whether alisertib improved ORR (complete response [CR] plus partial response) and/or PFS versus comparator on the basis of independent review committee (IRC) assessment using International Working Group 2007 criteria. 26 OS was the key secondary end point. Other secondary objectives included safety and tolerability; CR rate; time-to progression (TTP); time-to partial response or better (TTR); DOR; and time to subsequent antineoplastic therapy.
Eligible patients were age 18 years or older; had PTCL, including PTCL-NOS, anaplastic large-cell lymphoma, angioimmunoblastic T-cell lymphoma, enteropathy associated T-cell lymphoma, hepatosplenic T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma, transformed mycosis fungoides, or extranodal natural killer/ T-cell lymphoma nasal type; and developed relapsed or refractory disease after one or more prior systemic therapy. Eligibility criteria are described in the Data Supplement. 12 1 mg every 8 to 10 weeks and oral folic acid 1.0 to 1.25 mg per day. Cycles were repeated if patients continued to benefit from/tolerate therapy. Alisertib dose reductions-by one dose level or more, with minimum 10-mg decrements per cycle and a maximum of two reductions-were permitted in cases of drug-related toxicities. Dose reductions were allowed for comparators according to prescribing information.
Random Assignment and Treatment
Assessments
Adequate tumor tissue was required from all patients for disease subtyping by central review (Cleveland Clinic). Extent of disease was evaluated by International Working Group 2007 criteria. 26 Imaging scans were submitted for central independent review (IRC; BioClinica). Response was assessed every 8 weeks until 10 months (week 40), and every 12 weeks thereafter, using computed tomography and fluorodeoxyglucose-positron emission tomography until disease progression. Patients were observed for survival every 4 months. Adverse events (AEs) were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03).
Statistical Analysis
The intention-to-treat (ITT) population-all randomly assigned patients-was used for analysis of PFS, OS, TTR, and TTP. The per-protocol population, which consisted of ITT patients without major protocol violations, was used for sensitivity analyses. The safety population included all patients who received one or more doses of the study drug. The response-evaluable population-all patients with an eligible PTCL subtype (centrally confirmed), with measurable disease at baseline, who received one or more doses of the drug and who had one or more postbaseline response assessments by IRC-was used for analysis of ORR, CR rate, and DOR.
The study used an adaptive sample size re-estimation approach and exhaustive fallback procedure for type I error control. Study recruitment was capped at 354 patients to obtain a maximum of 261 PFS events, assuming 46 months of accrual, 8 months of additional follow-up, and an approximate 12% dropout rate, to detect a difference in median PFS of 6 months in the comparator arm and 9 months in the alisertib arm (85% power; a = .0125). This sample size also enabled testing of the assumption that ORR for the comparator arm was 30% and 55% for the alisertib arm (80% power; a = .0125), as well as to detect a 28.6% reduction in hazard ratio (HR) for OS (80% power; a = .025). Additional details of sample size calculation are provided in the Data Supplement. The study was not powered to identify statistically significant differences between alisertib and individual comparator treatments or between any two comparators.
An independent data monitoring committee reviewed unblinded safety and efficacy data at two planned interim analyses (IAs) and an additional ad hoc IA (Data Supplement). After the ad hoc IA, the independent data monitoring committee recommended halting enrolment as a result of a low probability of achieving superiority of alisertib over comparators.
RESULTS
Patients
Between May 31, 2012, and October 20, 2014, 271 patients were enrolled and randomly assigned to receive alisertib (n = 138) or comparator (n = 133; gemcitabine, n = 30; pralatrexate, n = 80; romidepsin, n = 23). The safety population consisted of 264 patients (alisertib, n = 137; comparator n = 127). Seven patients had no eligible PTCL subtype and did not receive a study dose (alisertib, n = 1; gemcitabine, n = 1; pralatrexate, n = 4; romidepsin, n = 1; Fig 1) .
At final data cutoff (June 30, 2015), 15 patients were continuing treatment, (alisertib, n = 9; comparator, n = 6 [all pralatrexate]). Treatment discontinuation was mainly because of progressive disease (PD) reported for 63 (46%) alisertib-treated and 52 (39%) comparator-treated patients (gemcitabine, n = 13; pralatrexate, n = 34; romidepsin, n = 5; Table 1 ). Baseline demographics and disease characteristics were generally balanced across treatment arms (Table 2) , including a median of two prior therapies.
Treatment Exposure
Alisertib-treated patients received a median of four (range, one to 50) 21-day treatment cycles, and 76 (55%) of 137 patients received four or more 4 cycles. Mean treatment duration was 20.8 weeks (range, 1 to 148 weeks). In the comparator arm, patients received a median of two (range, one to 17) cycles (28-day [gemcitabine and romidepsin] and 49-day [pralatrexate] cycles), and 38 (30%) of 127 patients received four or more cycles. Mean treatment duration was 16.6 weeks (range, 1 to 115 weeks). Treatment duration was 40 weeks or more for 24 patients (18%) on alisertib and 11 patients (9%) on comparators (all pralatrexate). Mean relative dose intensity was 92.9% for alisertib and 66.1% for comparators (gemcitabine, 73.5%; pralatrexate, 58.3%; romidepsin, 83.0%).
Efficacy
Central hematopathology confirmed only that 225 (83%) of 271 patients had an eligible PTCL subtype (discordance rate of 16% and 14% in alisertib and comparator arms, respectively). Forty-six patients who lacked PTCL or eligible PTCL subtype were excluded from the response-evaluable population. The Data Supplement provides additional details of diagnoses for these patients. An additional 31 patients were not response evaluable (did not receive one or more doses of the study drug and/or lacked postbaseline central response assessment). ORR was 33% (n = 34 of 102 patients) with alisertib versus 45% (n = 41 of 92 patients) with comparators (odds ratio, 0.60; 95% CI, 0.33 to 1.08; Table 3 ). CR rate with alisertib and comparators was 18% and 27%, respectively. ORR was 35% for gemcitabine (n = eight of 23 patients), 43% for pralatrexate (n = 22 of 51 patients), and 61% for romidepsin (n = 11 of 18 patients). ORR by PTCL subgroup with alisertib versus comparators was 37% versus 47% in PTCL-NOS, 28% versus 46% in angioimmunoblastic T-cell lymphoma, and 32% versus 38% in other eligible PTCL subtypes (patient numbers for the remaining individual subtypes were too low to assess separately for differences in ORR), respectively. The study was not powered to demonstrate significant response differences between comparator treatments; however, data are shown for ORR and PFS rates by the three major disease subtypes in the Data Supplement. Whereas the numbers of patients in the alisertib and comparator arms were fairly balanced across regions, there was a greater difference in ORR between treatment arms in North America (29% v 59% for alisertib v comparator) than in other regions (Western Europe: 33% v 36%; rest of world: 36% v 41%, respectively), possibly because romidepsin was available only in the United States (18 response-evaluable patients).
PD (57% v 47%) was a more common reason than death (11% v 18%) for a PFS event in both treatment arms. Median PFS was 115 versus 104 days for alisertib versus comparators, respectively (HR, 0.87; 95% CI, 0.644 to 1.162; Fig 2) . Start of alternate treatment by the investigator before documented PD led to censoring of 21% and 17% of patients on alisertib and comparators, respectively. Median PFS was 57 days (gemcitabine), 101 days (pralatrexate), and 242 days (romidepsin). On the basis of sensitivity analyses (per protocol population), median PFS was 120 days versus 104 days for alisertib versus comparators, respectively (HR, 0.82; 95% CI, 0.593 to 1.136; Data Supplement), and 58 days, 99 days, and 242 days for gemcitabine, pralatrexate, and romidepsin, respectively.
Median follow-up duration for OS was 519 days with alisertib and 586 days with comparators (75 deaths in each arm). Median OS was 415 days (13.7 months) with alisertib and 367 days ( †Patient was recorded as discontinuing study treatment as a result of initiation of hematopoietic stem-cell transplantation, but the patient experienced disease progression before the transplantation procedure could be performed. and 36% and 19% of alisertib-treated and comparator-treated patients, respectively, had an AE-related dose delay.
Serious AEs occurred in 55% of patients on alisertib and 54% on comparators-febrile neutropenia (17% v 2%, respectively), pyrexia (9% v 10%, respectively), pneumonia (6% v 2%, respectively), stomatitis (5% v 9%, respectively), thrombocytopenia (5% v 4%, respectively), and anemia (5% v 2%, respectively) were the most common serious AEs with alisertib. Overall, 26 on-study deaths were recorded (alisertib, n = 11 [8%]; and comparator, n = 15 [12%; gemcitabine, n = 5; pralatrexate, n = 8; romidepsin, n = 2]; Table 4 ). Of these, three (septic shock, n = 2; pneumonia, n = 1) in the alisertib group, one (adverse drug reaction) in the gemcitabine group, one (multiorgan failure) in the pralatrexate group, and none in the romidepsin group were considered drug related.
DISCUSSION
This phase III, two-arm, open-label study was the first randomized trial in relapsed/refractory PTCL at the time it was conducted. Single-agent alisertib demonstrated activity in patients with relapsed/refractory PTCL but was not superior to comparators in terms of ORR or PFS. The study was terminated after the ad hoc IA as a result of a low probability of demonstrating superiority of alisertib over comparator. Alisertib was administered at 50 mg two times per day for 7 consecutive days in 21-day cycles (the maximum tolerated dose on this dosing schedule, providing pharmacologically active exposures evidenced by pharmacokinetic and tumor pharmacodynamic evaluations performed in early clinical development). 27, 28 As such, this phase III trial evaluated a dose and schedule of alisertib that is maximally tolerated and expected to achieve maximal tumor pharmacodynamic effects during multiple dose administrations to provide a robust test of the therapeutic hypothesis for AAK inhibition in PTCL.
ORR with alisertib (33%) is consistent with phase II studies in relapsed/refractory PTCL (ORR, 30%) 14 and relapsed/ refractory non-Hodgkin lymphomas (ORR, 27%). 23 Nearly all patients on alisertib and comparators experienced one or more AE, and 88% and 94%, respectively, experienced drug-related AEs. Mean relative dose intensity for comparators was 66.1% (92.9% for alisertib), which means that more comparator-treated patients required AErelated dose modifications-33% of patients on comparators underwent one or more dose reductions (28% with alisertib). Taken together, these findings suggest that alisertib was better tolerated than comparators. Common alisertib-related toxicities were hematologic and GI, which is consistent with other single-agent alisertib studies, 14, [23] [24] [25] but manageable with dose reduction. One limitation of this study was that patients with a range of local diagnosisbased PTCL subtypes were enrolled, but 46 patients (17%) were subsequently identified by central expert review as lacking a protocol-eligible PTCL subtype-that is, no PTCL or inadequate tumor specimen. Therefore, the response-evaluable population was smaller than the safety population. Future studies should focus on selecting appropriate patient populations or confirming disease subtype before dosing while acknowledging that rapidly progressing diseases require prompt treatment initiation. Additional challenges in this trial included ensuring that investigators observed patients with required imaging to PD after the end of treatment and documented alternative therapy. This international phase III trial only enrolled patients in regions where the recommended dose of single-agent alisertib was 50 mg two times per day for 7 days in 21-day cycles. 31 Previous studies in East Asian patients have identified a higher bioavailability of alisertib in these populations, translating to a lower alisertib dose of 30 mg two times per day. 22, 32 Thus, the design of future Asia-inclusive global clinical trials of alisertib will need to incorporate exposurematched regional dosing with lower alisertib doses for East Asian patients. 33 Although alisertib did not demonstrate superior efficacy over comparators, it showed activity and acceptable tolerability and safety in patients with relapsed/refractory PTCL, as well as positive trends in sensitivity analyses for PFS, OS, DOR, and TTP. The study was not powered for comparison with single-agent comparators; however, alisertib resulted in a similar ORR and numerically longer PFS versus those of gemcitabine while having the potential benefits of an oral administration route rather than an intravenous delivery. Additional studies are required to investigate whether alisertib provides greater benefit in a subgroup of patients with PTCL who responded poorly to comparator agents and the potential for treatment combinations of alisertib with novel agents. efficacy data at the interim analyses. In addition, the authors acknowledge medical writing support from Yosef Mansour and Dawn Lee (FireKite, an Ashfield company, part of UDG Healthcare), which was funded by Millennium Pharmaceuticals (Cambridge, MA), a wholly owned subsidiary of Takeda Pharmaceuticals, in compliance with Good Publication Practice 3 ethical guidelines (Battisti et al: Ann Intern Med 163:461-464, 2015). Takeda Pharmaceuticals makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see https:// www.takedaclinicaltrials.com/ for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.
